NYSE:ALife Sciences
Agilent Technologies (A) Could Be 14% Undervalued Following FDA Cancer Test Approval
Agilent Technologies (A) stock is in focus after the company received U.S. Food and Drug Administration approval for its PD-L1 IHC 28-8 pharmDx assay, a companion diagnostic for several gastrointestinal cancers.
See our latest analysis for Agilent Technologies.
Against this FDA approval backdrop, Agilent Technologies’ share price of $137.89 sits after a 7 day share price return of 5.86% and a 90 day share price return of 20.04%. The 1 year total shareholder return of 16.28% points to momentum...